Kerendia: Bayer’s big opportunity to deliver for millions of patients, across indications

An interview with Bayer's Bernardo Kanahuati, senior vice president, global head cardiorenal and product team lead, Kerendia, and Katja Rohwedder, senior medical affairs physician, global medical affairs heart and kidney.

Bayer (BAYN: DE) has a prize asset on its hands with Kerendia (finerenone) and, more importantly, a solution for millions of patients.

It recently became the first-and-only non-steroidal mineralocorticoid receptor antagonist (MRA) to meet a primary composite cardiovascular endpoint in a Phase III trial investigating patients with heart failure (HF) with mildly reduced or preserved ejection fraction (LVEF ≥40%).